• Summary
  • Table Of Content
  • Segmentation
  • Request sample

Digital Biomarkers Market Overview

The Global Digital Biomarkers Market size is expected to grow from USD 3.56 billion in 2023 to USD 75.61 billion by 2032, at a CAGR of 40.43% during the forecast period (2024-2032)

The digital biomarkers industry represents a cutting-edge intersection of healthcare, technology, and data analytics, poised to revolutionize how we monitor and manage health conditions. Unlike traditional biomarkers, which are measurable indicators of biological processes or conditions, digital biomarkers are derived from data collected through digital devices such as smartphones, wearables, or sensors. This data includes physiological measurements, movement patterns, sleep quality, and even speech patterns, all of which can provide valuable insights into an individual's health status.

Digital biomarkers have a significant benefit in their capacity to collect data constantly in real-time, providing a more thorough and dynamic understanding of an individual's health in contrast to occasional clinic appointments or conventional testing procedures. This ongoing observation can facilitate timely identification of health problems, individualized treatments, and more accurate control of chronic conditions. Additionally, digital biomarkers make it easier to monitor patients remotely, which is becoming more important in a healthcare system that is shifting towards decentralized care and telemedicine.

Advancements in sensor technology, artificial intelligence, and data analytics are driving the growth of the digital biomarkers industry by enabling the interpretation and application of large amounts of health-related data. Businesses and research facilities are currently engaged in the creation and verification of fresh digital indicators in various areas such as heart disease, diabetes, mental health ailments, and neurological disorders. Regulatory bodies are also starting to create systems for verifying and authorizing digital biomarkers, enabling their incorporation into healthcare systems and clinical practice globally.

DIGITAL BIOMARKERS

Market Dynamics And Factors Of Digital Biomarkers Market

Drivers:

Need For Improved Diagnostics And Integration of Digital Devices To Monitor Health Propelling The Market

Companion diagnostics and biomarkers have become increasingly relevant in the practice of medicine, leading to improved diagnosis, treatment, and monitoring across several disease areas. It can be used to identify patients likely to respond well to certain drugs or treatment options. These diagnostics are often used in conjunction with a specific drug. For instance, the Oncomine Dx Target Test (Thermo Fisher Scientific, Inc.) helps in biomarker testing of non-small cell lung cancer (NSCLC) patients eligible for ROZLYTREK (entrectinib). The expansion of the digital biomarkers market can be attributed to an increase in the usage of connected digital devices and health-related mobile applications. These devices aid in a range of diagnostic and prognostic measurements over diverse disease areas including mental health, diabetes, neurological diseases, and cardiovascular diseases. Rising usage of smartphones and the emergence of smartwatches, which aid in tracking the physiological details of the person's health, boost the digital biomarkers market. Technological advances in the range of mobiles and digitally connected technologies further propel the digital biomarkers market. Significant product launches and approvals from the FDA also drive the digital biomarkers market. For instance, in April 2020, the U.S. FDA approved KardiaMobile, by AliveCor, an AI-enabled wearable device that is designed to monitor a person's vital signs. It helps detect three highly common forms of heart arrhythmias.

Restraints:

Stringent Regulations And Affordability Impede The Growth Of The Market

There are barriers to broad acceptance, as there are with any emergent technology. Not all health information can be found, collected, or used. Many digital biomarker therapies are still experimental rather than common. Clinical procedures, legacy systems, workplace culture, and EU and international legislation can all make new digital biomarker technology adoption and integration challenges. Furthermore, pricey and intrusive digital biomarker therapies hinder wider adoption and are often ineffective since they lengthen a patient's stay in the hospital rather than at home.

Opportunities:

Voice Based Digital Biomarker Presents Substantial Growth Opportunity

Voice-based digital biomarkers are a forerunner of a biological research and healthcare revolution to come. The quality of a patient's voice is both a clear indicator of their health and a new frontier in health evaluation. Technologies that allow for speech capture on daily consumer devices and then do symptom recognition and prediction have enormous promise in both research and clinical practice. However, because these biomarkers are so new, there are significant uncertainties regarding how to bring them to market and use them effectively. Analytical validation entails verifying the quality and consistency of data processing and computed measures, as well as determining test-retest reliability, demographic variability, and comparing measurements to reference standards. Clinical validity is the process of ensuring that a measure corresponds to clinical outcomes such as diagnosis, illness progression, and therapy response. We give guidelines for the sorts of an evaluation required for speech-based biomarkers in each of these areas, as well as examine published examples. The examples in this study are specific to speech-based biomarkers, but they may be utilized as a model for developing digital biomarkers in general. One of the primary facilitators of voice-based digital biomarkers is EVOCAL Health GmbH.

Segmentation Analysis Of Digital Biomarkers Market

By System Component, Data collection tools dominate the digital biomarkers market. The cheap cost and greater scalability of digital biomarkers based on smartphone applications make it possible to access previously unavailable social, behavioral, psychological, and environmental data. Due to its capacity to evaluate health status, the development and progression of illnesses, and health conditioning monitoring using a non-invasive technique in healthcare research, biosensors had a substantial digital biomarker market share in 2020.

By Therapeutic Area, Cardiovascular Disease accounted for the largest share of digital biomarkers in the market. In cardiovascular disorders, digital biomarkers provide greater in-depth insights into the heart response of individuals during standardized exercise. The data generated by digital biomarkers have the potential to improve cardiac rehabilitation outcomes by optimizing and improving patient-centric treatment techniques.

By End User, Biopharmaceutical dominates the Digital Biomarkers Market.  Digital biomarkers are thought to be most useful in the early stages of drug research when pharmaceutical experts need to know if the medicine is successful or not before moving on to a phase III study and validating the results. For example, in the case of Alzheimer's and Parkinson's illnesses, the effectiveness of the treatments cannot be confirmed until the phase III trial, which has resulted in high-profile, cost-prohibitive failures that have cost pharmaceutical companies millions of dollars in the drug development process.

Regional Analysis Of Digital Biomarkers Market

North America remains a frontrunner in the digital biomarkers market, driven by robust investments in healthcare technology and a supportive regulatory environment. The region is home to numerous pioneering companies and research institutions advancing digital biomarker development. Dominance in North America is bolstered by strong collaborations between technology firms, healthcare providers, and academic centers, fostering innovation and commercialization. The United States, in particular, leads in regulatory advancements, with the FDA increasingly engaging in discussions and guidelines for digital biomarker validation and integration into clinical practice.

Europe boasts a robust digital biomarkers landscape, led by countries like Germany, the UK, and France, which serve as key hubs for innovation and research in digital health. The region benefits from a diverse regulatory environment under the European Union, with bodies like the EMA actively paving the way for digital biomarker adoption. Meanwhile, Asia-Pacific is experiencing rapid growth driven by technological advancements and increased healthcare investments in nations such as China, Japan, and South Korea. Despite varying regulatory frameworks, the region's proactive stance on digital healthcare transformation fuels demand for solutions like digital biomarkers, addressing pressing healthcare needs like aging populations and chronic diseases.

The digital biomarkers industry is witnessing global expansion driven by technological innovation, regulatory advancements, and increasing healthcare needs. While North America and Europe lead in terms of market dominance and regulatory maturity, Asia-Pacific and emerging markets offer significant growth opportunities fueled by technological adoption and evolving healthcare landscapes.

Top Key Players Covered In Digital Biomarkers Market

  • AliveCor Inc.
  • Bayer AG
  • Evidation Health Inc.
  • Fitbit Inc.
  • Happify Health
  • Koninklijke Philips NV
  • Neurotrack Technologies Inc.
  • GlaxoSmithKline Inc.
  • Novartis International AG
  • F. Hoffmann-La Roche Ltd.

Key Industry Developments in Digital Biomarkers Market

  • In March 2024, Koneksa announced Merck's participation in its Data Syndication Partnership program for the LEARNS observational study on Parkinsonā€™s digital biomarkers. Merck, joining as a member, gained real-time access to study data from smartphone-based and wearable technology assessments. The collaboration aimed to advance digital measures for Parkinsonā€™s disease progression and treatment assessment through innovative data-sharing initiatives.
  • In February 2024, Biofourmis secured four new agreements with top-20 pharmaceutical firms, driven by its expertise in digital biomarker development and decentralized clinical trial solutions. These partnerships focused on advancing oncology therapies through cutting-edge data science and technology, enhancing remote patient monitoring and safety measures. The agreements expand Biofourmis' global clinical trial footprint, spanning key regions including the United States, Europe, Asia-Pacific, and the Middle East, reflecting a strategic alignment with industry trends towards digital endpoints in drug development.

Global Digital Biomarkers Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 3.56 Bn.

Forecast Period 2024-32 CAGR:

40.43%

Market Size in 2032:

USD 75.61 Bn.

Segments Covered:

By System Component

  • Data Collection Tools
  • Data Integration Systems

By Therapeutic Area

  • Cardiovascular Disease
  • Sleep and Movement Disease
  • Neurodegenerative Disorders
  • Psychiatric Disorder
  • Gastrointestinal Disease
  • Respiratory Disease
  • Diabetes
  • Others

By End-User

  • Biopharmaceutical
  • Providers
  • Payers

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Need for Improved Diagnostics and Integration of Digital Devices to Monitor Health Propelling the Market

Key Market Restraints:

  • Stringent Regulations and Affordability Impede the Growth of The Market

Key Opportunities:

  • Voice Based Digital Biomarker Presents Substantial Growth Opportunity

Companies Covered in the report:

  • AliveCor Inc., Bayer AG, Evidation Health Inc., Fitbit Inc., Happify Health and other major players.

Chapter 1: Introduction
ā€ƒ1.1 Research Objectives
ā€ƒ1.2 Research Methodology
ā€ƒ1.3 Research Process
ā€ƒ1.4 Scope and Coverage
ā€ƒā€ƒ1.4.1 Market Definition
ā€ƒā€ƒ1.4.2 Key Questions Answered
ā€ƒ1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
ā€ƒ3.1 By System Component
ā€ƒ3.2 By Therapeutic Area
ā€ƒ3.3 By End User

Chapter 4: Market Landscape
ā€ƒ4.1 Porter's Five Forces Analysis
ā€ƒā€ƒ4.1.1 Bargaining Power of Supplier
ā€ƒā€ƒ4.1.2 Threat of New Entrants
ā€ƒā€ƒ4.1.3 Threat of Substitutes
ā€ƒā€ƒ4.1.4 Competitive Rivalry
ā€ƒā€ƒ4.1.5 Bargaining Power Among Buyers
ā€ƒ4.2 Industry Value Chain Analysis
ā€ƒ4.3 Market Dynamics
ā€ƒā€ƒ3.5.1 Drivers
ā€ƒā€ƒ3.5.2 Restraints
ā€ƒā€ƒ3.5.3 Opportunities
ā€ƒā€ƒ3.5.4 Challenges
ā€ƒ4.4 Pestle Analysis
ā€ƒ4.5 Technological Roadmap
ā€ƒ4.6 Regulatory Landscape
ā€ƒ4.7 SWOT Analysis
ā€ƒ4.8 Price Trend Analysis
ā€ƒ4.9 Patent Analysis
ā€ƒ4.10 Analysis of the Impact of Covid-19
ā€ƒā€ƒ4.10.1 Impact on the Overall Market
ā€ƒā€ƒ4.10.2 Impact on the Supply Chain
ā€ƒā€ƒ4.10.3 Impact on the Key Manufacturers
ā€ƒā€ƒ4.10.4 Impact on the Pricing

Chapter 4: Digital Biomarkers Market by System Component
ā€ƒ4.1 Digital Biomarkers Market Overview Snapshot and Growth Engine
ā€ƒ4.2 Digital Biomarkers Market Overview
ā€ƒ4.3 Data Collection Tools
ā€ƒā€ƒ4.3.1 Introduction and Market Overview
ā€ƒā€ƒ4.3.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ4.3.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ4.3.4 Data Collection Tools: Grographic Segmentation
ā€ƒ4.4 Data Integration Systems
ā€ƒā€ƒ4.4.1 Introduction and Market Overview
ā€ƒā€ƒ4.4.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ4.4.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ4.4.4 Data Integration Systems: Grographic Segmentation

Chapter 5: Digital Biomarkers Market by Therapeutic Area
ā€ƒ5.1 Digital Biomarkers Market Overview Snapshot and Growth Engine
ā€ƒ5.2 Digital Biomarkers Market Overview
ā€ƒ5.3 Cardiovascular Disease
ā€ƒā€ƒ5.3.1 Introduction and Market Overview
ā€ƒā€ƒ5.3.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ5.3.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ5.3.4 Cardiovascular Disease: Grographic Segmentation
ā€ƒ5.4 Sleep and Movement Disease
ā€ƒā€ƒ5.4.1 Introduction and Market Overview
ā€ƒā€ƒ5.4.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ5.4.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ5.4.4 Sleep and Movement Disease: Grographic Segmentation
ā€ƒ5.5 Neurodegenerative Disorders
ā€ƒā€ƒ5.5.1 Introduction and Market Overview
ā€ƒā€ƒ5.5.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ5.5.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ5.5.4 Neurodegenerative Disorders: Grographic Segmentation
ā€ƒ5.6 Psychiatric Disorder
ā€ƒā€ƒ5.6.1 Introduction and Market Overview
ā€ƒā€ƒ5.6.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ5.6.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ5.6.4 Psychiatric Disorder: Grographic Segmentation
ā€ƒ5.7 Gastrointestinal Disease
ā€ƒā€ƒ5.7.1 Introduction and Market Overview
ā€ƒā€ƒ5.7.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ5.7.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ5.7.4 Gastrointestinal Disease: Grographic Segmentation
ā€ƒ5.8 Respiratory Disease
ā€ƒā€ƒ5.8.1 Introduction and Market Overview
ā€ƒā€ƒ5.8.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ5.8.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ5.8.4 Respiratory Disease: Grographic Segmentation
ā€ƒ5.9 Diabetes
ā€ƒā€ƒ5.9.1 Introduction and Market Overview
ā€ƒā€ƒ5.9.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ5.9.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ5.9.4 Diabetes: Grographic Segmentation
ā€ƒ5.10 Others
ā€ƒā€ƒ5.10.1 Introduction and Market Overview
ā€ƒā€ƒ5.10.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ5.10.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ5.10.4 Others: Grographic Segmentation

Chapter 6: Digital Biomarkers Market by End User
ā€ƒ6.1 Digital Biomarkers Market Overview Snapshot and Growth Engine
ā€ƒ6.2 Digital Biomarkers Market Overview
ā€ƒ6.3 Biopharmaceutical
ā€ƒā€ƒ6.3.1 Introduction and Market Overview
ā€ƒā€ƒ6.3.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ6.3.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ6.3.4 Biopharmaceutical: Grographic Segmentation
ā€ƒ6.4 Providers
ā€ƒā€ƒ6.4.1 Introduction and Market Overview
ā€ƒā€ƒ6.4.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ6.4.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ6.4.4 Providers: Grographic Segmentation
ā€ƒ6.5 Payers
ā€ƒā€ƒ6.5.1 Introduction and Market Overview
ā€ƒā€ƒ6.5.2 Historic and Forecasted Market Size (2017-2032F)
ā€ƒā€ƒ6.5.3 Key Market Trends, Growth Factors and Opportunities
ā€ƒā€ƒ6.5.4 Payers: Grographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
ā€ƒ7.1 Competitive Landscape
ā€ƒā€ƒ7.1.1 Competitive Positioning
ā€ƒā€ƒ7.1.2 Digital Biomarkers Sales and Market Share By Players
ā€ƒā€ƒ7.1.3 Industry BCG Matrix
ā€ƒā€ƒ7.1.4 Ansoff Matrix
ā€ƒā€ƒ7.1.5 Digital Biomarkers Industry Concentration Ratio (CR5 and HHI)
ā€ƒā€ƒ7.1.6 Top 5 Digital Biomarkers Players Market Share
ā€ƒā€ƒ7.1.7 Mergers and Acquisitions
ā€ƒā€ƒ7.1.8 Business Strategies By Top Players
ā€ƒ7.2 ALIVECOR INC.
ā€ƒā€ƒ7.2.1 Company Overview
ā€ƒā€ƒ7.2.2 Key Executives
ā€ƒā€ƒ7.2.3 Company Snapshot
ā€ƒā€ƒ7.2.4 Operating Business Segments
ā€ƒā€ƒ7.2.5 Product Portfolio
ā€ƒā€ƒ7.2.6 Business Performance
ā€ƒā€ƒ7.2.7 Key Strategic Moves and Recent Developments
ā€ƒā€ƒ7.2.8 SWOT Analysis
ā€ƒ7.3 BAYER AG
ā€ƒ7.4 EVIDATION HEALTH INC.
ā€ƒ7.5 FITBIT INC.
ā€ƒ7.6 HAPPIFY HEALTH
ā€ƒ7.7 KONINKLIJKE PHILIPS NV
ā€ƒ7.8 NEUROTRACK TECHNOLOGIES INC.
ā€ƒ7.9 GLAXOSMITHKLINE INC.
ā€ƒ7.10 NOVARTIS INTERNATIONAL AG
ā€ƒ7.11 F. HOFFMANN-LA ROCHE LTD.

Chapter 8: Global Digital Biomarkers Market Analysis, Insights and Forecast, 2017-2032
ā€ƒ8.1 Market Overview
ā€ƒ8.2 Historic and Forecasted Market Size By System Component
ā€ƒā€ƒ8.2.1 Data Collection Tools
ā€ƒā€ƒ8.2.2 Data Integration Systems
ā€ƒ8.3 Historic and Forecasted Market Size By Therapeutic Area
ā€ƒā€ƒ8.3.1 Cardiovascular Disease
ā€ƒā€ƒ8.3.2 Sleep and Movement Disease
ā€ƒā€ƒ8.3.3 Neurodegenerative Disorders
ā€ƒā€ƒ8.3.4 Psychiatric Disorder
ā€ƒā€ƒ8.3.5 Gastrointestinal Disease
ā€ƒā€ƒ8.3.6 Respiratory Disease
ā€ƒā€ƒ8.3.7 Diabetes
ā€ƒā€ƒ8.3.8 Others
ā€ƒ8.4 Historic and Forecasted Market Size By End User
ā€ƒā€ƒ8.4.1 Biopharmaceutical
ā€ƒā€ƒ8.4.2 Providers
ā€ƒā€ƒ8.4.3 Payers

Chapter 9: North America Digital Biomarkers Market Analysis, Insights and Forecast, 2017-2032
ā€ƒ9.1 Key Market Trends, Growth Factors and Opportunities
ā€ƒ9.2 Impact of Covid-19
ā€ƒ9.3 Key Players
ā€ƒ9.4 Key Market Trends, Growth Factors and Opportunities
ā€ƒ9.4 Historic and Forecasted Market Size By System Component
ā€ƒā€ƒ9.4.1 Data Collection Tools
ā€ƒā€ƒ9.4.2 Data Integration Systems
ā€ƒ9.5 Historic and Forecasted Market Size By Therapeutic Area
ā€ƒā€ƒ9.5.1 Cardiovascular Disease
ā€ƒā€ƒ9.5.2 Sleep and Movement Disease
ā€ƒā€ƒ9.5.3 Neurodegenerative Disorders
ā€ƒā€ƒ9.5.4 Psychiatric Disorder
ā€ƒā€ƒ9.5.5 Gastrointestinal Disease
ā€ƒā€ƒ9.5.6 Respiratory Disease
ā€ƒā€ƒ9.5.7 Diabetes
ā€ƒā€ƒ9.5.8 Others
ā€ƒ9.6 Historic and Forecasted Market Size By End User
ā€ƒā€ƒ9.6.1 Biopharmaceutical
ā€ƒā€ƒ9.6.2 Providers
ā€ƒā€ƒ9.6.3 Payers
ā€ƒ9.7 Historic and Forecast Market Size by Country
ā€ƒā€ƒ9.7.1 U.S.
ā€ƒā€ƒ9.7.2 Canada
ā€ƒā€ƒ9.7.3 Mexico

Chapter 10: Europe Digital Biomarkers Market Analysis, Insights and Forecast, 2017-2032
ā€ƒ10.1 Key Market Trends, Growth Factors and Opportunities
ā€ƒ10.2 Impact of Covid-19
ā€ƒ10.3 Key Players
ā€ƒ10.4 Key Market Trends, Growth Factors and Opportunities
ā€ƒ10.4 Historic and Forecasted Market Size By System Component
ā€ƒā€ƒ10.4.1 Data Collection Tools
ā€ƒā€ƒ10.4.2 Data Integration Systems
ā€ƒ10.5 Historic and Forecasted Market Size By Therapeutic Area
ā€ƒā€ƒ10.5.1 Cardiovascular Disease
ā€ƒā€ƒ10.5.2 Sleep and Movement Disease
ā€ƒā€ƒ10.5.3 Neurodegenerative Disorders
ā€ƒā€ƒ10.5.4 Psychiatric Disorder
ā€ƒā€ƒ10.5.5 Gastrointestinal Disease
ā€ƒā€ƒ10.5.6 Respiratory Disease
ā€ƒā€ƒ10.5.7 Diabetes
ā€ƒā€ƒ10.5.8 Others
ā€ƒ10.6 Historic and Forecasted Market Size By End User
ā€ƒā€ƒ10.6.1 Biopharmaceutical
ā€ƒā€ƒ10.6.2 Providers
ā€ƒā€ƒ10.6.3 Payers
ā€ƒ10.7 Historic and Forecast Market Size by Country
ā€ƒā€ƒ10.7.1 Germany
ā€ƒā€ƒ10.7.2 U.K.
ā€ƒā€ƒ10.7.3 France
ā€ƒā€ƒ10.7.4 Italy
ā€ƒā€ƒ10.7.5 Russia
ā€ƒā€ƒ10.7.6 Spain

Chapter 11: Asia-Pacific Digital Biomarkers Market Analysis, Insights and Forecast, 2017-2032
ā€ƒ11.1 Key Market Trends, Growth Factors and Opportunities
ā€ƒ11.2 Impact of Covid-19
ā€ƒ11.3 Key Players
ā€ƒ11.4 Key Market Trends, Growth Factors and Opportunities
ā€ƒ11.4 Historic and Forecasted Market Size By System Component
ā€ƒā€ƒ11.4.1 Data Collection Tools
ā€ƒā€ƒ11.4.2 Data Integration Systems
ā€ƒ11.5 Historic and Forecasted Market Size By Therapeutic Area
ā€ƒā€ƒ11.5.1 Cardiovascular Disease
ā€ƒā€ƒ11.5.2 Sleep and Movement Disease
ā€ƒā€ƒ11.5.3 Neurodegenerative Disorders
ā€ƒā€ƒ11.5.4 Psychiatric Disorder
ā€ƒā€ƒ11.5.5 Gastrointestinal Disease
ā€ƒā€ƒ11.5.6 Respiratory Disease
ā€ƒā€ƒ11.5.7 Diabetes
ā€ƒā€ƒ11.5.8 Others
ā€ƒ11.6 Historic and Forecasted Market Size By End User
ā€ƒā€ƒ11.6.1 Biopharmaceutical
ā€ƒā€ƒ11.6.2 Providers
ā€ƒā€ƒ11.6.3 Payers
ā€ƒ11.7 Historic and Forecast Market Size by Country
ā€ƒā€ƒ11.7.1 China
ā€ƒā€ƒ11.7.2 India
ā€ƒā€ƒ11.7.3 Japan
ā€ƒā€ƒ11.7.4 Southeast Asia

Chapter 12: South America Digital Biomarkers Market Analysis, Insights and Forecast,2017-2032
ā€ƒ12.1 Key Market Trends, Growth Factors and Opportunities
ā€ƒ12.2 Impact of Covid-19
ā€ƒ12.3 Key Players
ā€ƒ12.4 Key Market Trends, Growth Factors and Opportunities
ā€ƒ12.4 Historic and Forecasted Market Size By System Component
ā€ƒā€ƒ12.4.1 Data Collection Tools
ā€ƒā€ƒ12.4.2 Data Integration Systems
ā€ƒ12.5 Historic and Forecasted Market Size By Therapeutic Area
ā€ƒā€ƒ12.5.1 Cardiovascular Disease
ā€ƒā€ƒ12.5.2 Sleep and Movement Disease
ā€ƒā€ƒ12.5.3 Neurodegenerative Disorders
ā€ƒā€ƒ12.5.4 Psychiatric Disorder
ā€ƒā€ƒ12.5.5 Gastrointestinal Disease
ā€ƒā€ƒ12.5.6 Respiratory Disease
ā€ƒā€ƒ12.5.7 Diabetes
ā€ƒā€ƒ12.5.8 Others
ā€ƒ12.6 Historic and Forecasted Market Size By End User
ā€ƒā€ƒ12.6.1 Biopharmaceutical
ā€ƒā€ƒ12.6.2 Providers
ā€ƒā€ƒ12.6.3 Payers
ā€ƒ12.7 Historic and Forecast Market Size by Country
ā€ƒā€ƒ12.7.1 Brazil
ā€ƒā€ƒ12.7.2 Argentina

Chapter 13: Middle East & Africa Digital Biomarkers Market Analysis, Insights and Forecast,2017-2032
ā€ƒ13.1 Key Market Trends, Growth Factors and Opportunities
ā€ƒ13.2 Impact of Covid-19
ā€ƒ13.3 Key Players
ā€ƒ13.4 Key Market Trends, Growth Factors and Opportunities
ā€ƒ13.4 Historic and Forecasted Market Size By System Component
ā€ƒā€ƒ13.4.1 Data Collection Tools
ā€ƒā€ƒ13.4.2 Data Integration Systems
ā€ƒ13.5 Historic and Forecasted Market Size By Therapeutic Area
ā€ƒā€ƒ13.5.1 Cardiovascular Disease
ā€ƒā€ƒ13.5.2 Sleep and Movement Disease
ā€ƒā€ƒ13.5.3 Neurodegenerative Disorders
ā€ƒā€ƒ13.5.4 Psychiatric Disorder
ā€ƒā€ƒ13.5.5 Gastrointestinal Disease
ā€ƒā€ƒ13.5.6 Respiratory Disease
ā€ƒā€ƒ13.5.7 Diabetes
ā€ƒā€ƒ13.5.8 Others
ā€ƒ13.6 Historic and Forecasted Market Size By End User
ā€ƒā€ƒ13.6.1 Biopharmaceutical
ā€ƒā€ƒ13.6.2 Providers
ā€ƒā€ƒ13.6.3 Payers
ā€ƒ13.7 Historic and Forecast Market Size by Country
ā€ƒā€ƒ13.7.1 Saudi Arabia
ā€ƒā€ƒ13.7.2 South Africa

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

Global Digital Biomarkers Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 3.56 Bn.

Forecast Period 2024-32 CAGR:

40.43%

Market Size in 2032:

USD 75.61 Bn.

Segments Covered:

By System Component

  • Data Collection Tools
  • Data Integration Systems

By Therapeutic Area

  • Cardiovascular Disease
  • Sleep and Movement Disease
  • Neurodegenerative Disorders
  • Psychiatric Disorder
  • Gastrointestinal Disease
  • Respiratory Disease
  • Diabetes
  • Others

By End-User

  • Biopharmaceutical
  • Providers
  • Payers

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Need for Improved Diagnostics and Integration of Digital Devices to Monitor Health Propelling the Market

Key Market Restraints:

  • Stringent Regulations and Affordability Impede the Growth of The Market

Key Opportunities:

  • Voice Based Digital Biomarker Presents Substantial Growth Opportunity

Companies Covered in the report:

  • AliveCor Inc., Bayer AG, Evidation Health Inc., Fitbit Inc., Happify Health and other major players.
Please Wait...

Frequently Asked Questions :

What would be forecast period in the Digital Biomarkers Market research report?

The forecast period in the market research report is 2024-2032.

Who are the key players in Digital Biomarkers Market?

AliveCor Inc., Bayer AG, Evidation Health Inc., Fitbit Inc., Happify Health, and Other major players.

What are the segments of Digital Biomarkers Market?

The Digital Biomarkers market is segmented into System Component, Therapeutic Area, End-Use ,Region. Digital Biomarkers Market is segmented by, By System Component (Data Collection Tools, Data Integration Systems), By Therapeutic Area (Cardiovascular Disease, Sleep and Movement Disease, Neurodegenerative Disorders, Psychiatric Disorder, Gastrointestinal Disease, Respiratory Disease, Diabetes, Others), By End-User (Biopharmaceutical, Providers, Payers), Region - Global Market Analysis And Forecast 2022- 2028, By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain etc.), Asia-Pacific (China; India; Japan; Southeast Asia etc.), South America (Brazil; Argentina etc.), Middle East & Africa (Saudi Arabia; South Africa etc.).

What is the Digital Biomarkers market?

Digital biomarkers are physiological and behavioral data that are gathered and assessed using digital devices such as portables, wearables, implantable, or digestible.

How big is the Digital Biomarkers market?

The Global Digital Biomarkers Market size is expected to grow from USD 3.56 billion in 2023 to USD 75.61 billion by 2032, at a CAGR of 40.43% during the forecast period (2024-2032)